



Patient Capital Fourth Quarter Commentary

In the fourth quarter of 2025, North American equity markets extended gains, but Canada notably outpaced the U.S. The S&P/TSX Composite Total Return Index continued to benefit from its heavier exposure to cyclical and commodity-linked areas. Strength in mining shares and energy helped the index.

Monetary policy was supportive into year-end adding to the positive sentiment. The Federal Reserve cut rates in December 2025, lowering the target range for the federal funds rate by twenty-five basis points to 3.5%-3.75%. In Canada, the Bank of Canada held its policy rate at 2.25% in its December 10, 2025, decision, maintaining a stance that was broadly consistent with inflation being under better control.

The U.S. economy in the fourth quarter of 2025 continued to look resilient but cooling strong enough to support corporate fundamentals, yet soft enough to justify easing. Inflation data at year-end showed headline CPI up 2.7% year over year in December 2025, indicating that inflation remained materially lower than peak levels and relatively stable heading into 2026. Canada's economic picture in the fourth quarter was mixed. While inflation was near target levels, unemployment levels remained high and growth slowed.




PATIENT CAPITAL
MANAGEMENT INC.

Vito Maida,
Portfolio Manager
[LinkedIn Profile](#)

LYZ905
Lysander-Patient Capital
Equity Fund



As the Chart below indicates, the price of gold has risen dramatically in the past year and is at all time highs.



Investors typically jump into gold in times of uncertainty. Geopolitical risks are elevated compared with recent years. The threat of a broader European war arising out of the Ukraine/Russia conflict, and concerns over China's possible invasion of Taiwan have all been well reported. More recently, the invasion of Venezuela and protests in Tehran have added to geopolitical tensions.

Typically, major indices fall as investors flee to gold as protection against the aforementioned risks. However, during the past year, North American markets have reached record highs. This situation is highly unusual and intellectually inconsistent. Intellectual inconsistencies eventually correct themselves. In this case, the geopolitical concern(s) materialize and impact equity markets negatively, or they pass without major incident(s) and the price of gold falls.

We believe Lysander Patient Capital Equity Fund (the "Fund") continues to be positioned for current market conditions. As of December 31, 2025, the Fund's total portfolio yield was 4.2% and the portfolio's overall characteristics continue to compare favorably to major equity indexes such as the S&P 500 Index, and the S&P/TSX Composite. Relative performance versus the S&P 500 and the S&P/TSX Composite Total Return Index in 2025 was influenced by a lack of exposure to mega-cap technology and precious metals and materials companies in the United States and Canada, respectively. The Fund's value-based investment philosophy

remains disciplined and, in our view, is designed to compound through cycles by emphasizing fundamentals and valuation rather than chasing momentum, especially in years when index returns are driven by narrow leadership.

Lysander Funds Limited

WWW.LYSANDERFUNDSCOM

TORONTO Head Office

4000 – 3080 Yonge Street
Toronto, ON M4N 3N1

T. (416) 640-4275

F. (416) 855-6515

TF. 1 (877) 308-6979

E. manager@lysanderfunds.com

Follow Us on [LinkedIn](#) 

MONTRÉAL

3150 - 1 Place Ville Marie
Montréal, QC, H3B 3Y2

T. (514) 316-9257

VANCOUVER

1280 - 333 Seymour Street
Vancouver, BC, V6B 5A6

TF. 1 (877) 308-6979



IMPORTANT DISCLAIMER

Lysander Funds Limited ("Lysander") is the investment fund manager of Lysander-Patient Capital Equity Fund (the "Fund"). Patient Capital Management ("Patient Capital") is the portfolio manager of the Fund. This document was prepared by Patient Capital as portfolio manager of the Fund. In this presentation, "we", "us", and "our" means Patient Capital. This document has been prepared solely for information purposes. Information in this document is not intended to constitute legal, tax, securities or investment advice and is made available on an "as is" basis. Neither Lysander nor Patient Capital make any warranties or representations regarding the information herein. Information in this document is subject to change without notice. Neither Lysander nor Patient Capital assume any duty to update any information herein. Certain information in this document has been derived or obtained from sources believed to be trustworthy and/or reliable. Neither Lysander nor Patient Capital assume responsibility for the accuracy, currency, reliability or correctness of any such information.

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.

This document is not an invitation to invest in the Fund and does not constitute a public offering of sale. Purchases in the Fund can only be made through an Investment Professional on the terms in the applicable Fund's offering document by eligible investors. Each purchaser of units in a fund may have statutory or contractual right of action.

This document may contain forward-looking statements. Statements concerning a Fund's or entity's objectives, goals, strategies, intentions, plans, beliefs, expectations and estimates, and the business, operations, financial performance and condition are forward looking statements. The words "believe", "expect", "anticipate", "estimate", "intend", "aims", "may", "will", "would" and similar expressions and the negative of such expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations. Readers are cautioned not to place undue reliance on these forward-looking statements. While Lysander and Patient Capital consider these risks and uncertainties to be reasonable based on information currently available, they may prove to be incorrect.

Nothing in this document should be considered a recommendation to buy, sell or short a particular security. Any specific securities or positions discussed are intended as an illustration of the portfolio manager's selection process. The portfolio manager may sell these positions at any time, or purchase positions that have previously been sold. The positions may increase or decrease in value after the date hereof, and the portfolio that holds such positions may accordingly gain or lose money on the investment. The statements by the portfolio manager in its commentaries are intended to illustrate its approach in managing the portfolio and should not be relied upon for any other purpose. Certain information in this document has been derived or obtained from sources believed to be trustworthy and/or reliable. Neither Lysander nor Patient Capital assume responsibility for the accuracy, currency, reliability or correctness of any such information.

The S&P/TSX Composite Total Return Index is comprised of equity securities of some of the largest companies in Canada. The S&P 500 Index tracks the stock performance of 500 large companies listed on exchanges in the United States. An investor cannot invest directly in an index.

®Lysander Funds is a registered trademark of Lysander Funds Limited.

